Genmab AS Valuation
| GMAB Stock | USD 19.81 0.04 0.20% |
At this time, the firm appears to be undervalued. Genmab AS retains a regular Real Value of $23.4 per share. The prevalent price of the firm is $19.81. Our model calculates the value of Genmab AS from evaluating the firm fundamentals such as Return On Equity of 0.15, current valuation of 9.85 B, and Return On Asset of 0.11 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Genmab AS's valuation include:
Price Book 2.8222 | Enterprise Value | Enterprise Value Ebitda 10.0943 | Price Sales 0.6354 | Forward PE 13.986 |
Undervalued
Today
Please note that Genmab AS's price fluctuation is very steady at this time. Calculation of the real value of Genmab AS is based on 3 months time horizon. Increasing Genmab AS's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Genmab AS is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Genmab Stock. However, Genmab AS's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 19.81 | Real 23.4 | Target 36.56 | Hype 19.87 | Naive 19.04 |
The real value of Genmab Stock, also known as its intrinsic value, is the underlying worth of Genmab AS Company, which is reflected in its stock price. It is based on Genmab AS's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Genmab AS's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Genmab AS helps investors to forecast how Genmab stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Genmab AS more accurately as focusing exclusively on Genmab AS's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Genmab AS's intrinsic value based on its ongoing forecasts of Genmab AS's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Genmab AS's closest peers. If more than one evaluation category is relevant for Genmab AS we suggest using both methods to arrive at a better estimate.
Genmab AS Cash |
|
Genmab Valuation Trend
Comparing Genmab AS's enterprise value against its market capitalization is a good way to estimate the value of Genmab AS uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Genmab AS Total Value Analysis
Genmab AS is currently forecasted to have valuation of 9.85 B with market capitalization of 12.61 B, debt of 770 M, and cash on hands of 21.61 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Genmab AS fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
9.85 B | 12.61 B | 770 M | 21.61 B |
Genmab AS Investor Information
The book value of the company was currently reported as 502.6. The company has Price/Earnings To Growth (PEG) ratio of 0.71. Genmab AS had not issued any dividends in recent years. The entity had 5:1 split on the 1st of May 2018. Based on the key indicators related to Genmab AS's liquidity, profitability, solvency, and operating efficiency, Genmab AS is doing better financially today then in previous quarter. It has a moderate odds of reporting better financial numbers in March.Genmab AS Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Genmab AS has an asset utilization ratio of 46.68 percent. This suggests that the Company is making $0.47 for each dollar of assets. An increasing asset utilization means that Genmab AS is more efficient with each dollar of assets it utilizes for everyday operations.Genmab AS Ownership Allocation
Genmab AS has a total of 635.24 Million outstanding shares. Roughly 91.58 (percent) of Genmab AS outstanding shares are held by general public with 0.007 % owned by insiders and only 8.41 pct. by outside corporations. On January 15, 2025, Representative Josh Gottheimer of US Congress acquired under $15k worth of Genmab AS's common stock.Genmab AS Profitability Analysis
The company reported the previous year's revenue of 16.47 B. Net Income was 5.64 B with profit before overhead, payroll, taxes, and interest of 19.07 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Genmab AS's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Genmab AS and how it compares across the competition.
About Genmab AS Valuation
The stock valuation mechanism determines Genmab AS's current worth on a weekly basis. Our valuation model uses a comparative analysis of Genmab AS. We calculate exposure to Genmab AS's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Genmab AS's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 18.7 B | 19.6 B | |
| Pretax Profit Margin | 0.39 | 0.37 | |
| Operating Profit Margin | 0.37 | 0.35 | |
| Net Profit Margin | 0.30 | 0.29 | |
| Gross Profit Margin | 1.13 | 1.19 |
Genmab AS Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 65.9 M | |
| Quarterly Earnings Growth Y O Y | -0.38 | |
| Forward Price Earnings | 13.986 |
Genmab AS Current Valuation Indicators
Valuation refers to the process of determining the present value of Genmab AS and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Genmab we look at many different elements of the entity such as Genmab's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Genmab AS, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Genmab AS's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Genmab AS's worth.Complementary Tools for Genmab Stock analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |